Guardant Health, Inc.
GH
Positions held
Your positionsGH isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Guardant Health operates in the rapidly growing diagnostics and research sector, focusing on precision medicine and cancer detection, which positions it well against competitors in the industry.
- Revenue increased by 11% compared to the prior quarter, reaching $335 million.
- Gross margin improved to 65.4%, up from 65.2% in the previous quarter.
- The company has a negative profit margin of -38.33%, indicating ongoing financial challenges.
- Operating margin remains negative at -38.5%, reflecting continued operational difficulties.
- Net income for the latest quarter was -120.142 million, highlighting persistent losses.
Fundamentals
| Market cap | $22.22B | Enterprise value | $22.86B | Trailing P/E | — | Forward P/E | -396.14 |
| PEG | — | Price / book | -99.26 | Beta | 1.58 | Dividend yield | 0.00% |
| Revenue growth | 44.3% | Earnings growth | — | Gross margin | 65.0% | Operating margin | -38.2% |
| Profit margin | -38.3% | ROE | — | ROA | -18.1% | Debt / equity | — |
| Current ratio | 4.03 | Free cash flow | $26.61M | Analyst recommendation | strong_buy | Mean target | $200.24 |
| 52w high | $191.05 | 52w low | $61.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $335M | $302M | $281M | $265M | $232M |
| Op margin | -38.5% | -40.2% | -43.0% | -37.3% | -45.9% |
| Net income | -$120M | -$112M | -$128M | -$92.7M | -$99.9M |
| Gross margin | 65.4% | 65.2% | 64.6% | 64.7% | 65.0% |
| Gross profit | $219M | $197M | $182M | $172M | $151M |
| Operating income | -$129M | -$121M | -$121M | -$99.0M | -$106M |
- Revenue +11% vs prior quarter ($335M vs $302M).
- Gross margin 65.4% (was 65.2% prior quarter).
- Operating margin expanded to -38.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $982M | $739M | $564M | $450M | — |
| Op margin | -44.5% | -60.0% | -100.1% | -121.1% | — |
| Net income | -$416M | -$436M | -$479M | -$655M | — |
| Gross margin | 64.5% | 60.8% | 59.7% | 65.2% | — |
| Gross profit | $633M | $449M | $337M | $293M | — |
| Operating income | -$437M | -$444M | -$565M | -$544M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Guardant Gets European Approval for Guardant360 as Companion Diagnostic for AstraZeneca's Etcamah in Breast Cancer
2026-10-08 · Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
2026-10-07 · Dow Jones Futures Fall, Yields Jump After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys
2026-10-05 · 3 Cash-Burning Stocks with Questionable Fundamentals
2026-10-02 · These IBD 50 Stocks Are Stalled. That Could Be A Good Thing.
2026-09-30 · Abbott launches Freenome’s colorectal cancer screening test
2026-09-29 · 1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore
2026-09-29 · Coverbase Adds Third-Party Risk Veterans as Enterprise Adoption Accelerates
2026-09-24 · FDA Advisors Said It Should Approve the Grail Multicancer Blood Test. The Stock Rises Sharply.
Price (daily)
Full chart · RSI · MACD · patterns